Prudential Financial Inc. Acquires Shares of 10,415 TScan Therapeutics, Inc. (NASDAQ:TCRX)

Prudential Financial Inc. bought a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,415 shares of the company’s stock, valued at approximately $32,000.

A number of other large investors have also made changes to their positions in the stock. State Street Corp lifted its position in TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after buying an additional 148,414 shares in the last quarter. abrdn plc raised its holdings in shares of TScan Therapeutics by 137.8% during the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after acquiring an additional 512,049 shares during the period. Geode Capital Management LLC raised its holdings in shares of TScan Therapeutics by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock worth $4,849,000 after acquiring an additional 72,967 shares during the period. Stifel Financial Corp boosted its position in shares of TScan Therapeutics by 3.9% during the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock valued at $494,000 after acquiring an additional 3,733 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in TScan Therapeutics during the third quarter worth about $112,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Friday, March 14th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Thursday, March 6th. Barclays cut their target price on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price target on shares of TScan Therapeutics in a research note on Tuesday. Finally, Wedbush reissued an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $9.33.

TScan Therapeutics Stock Up 9.7 %

NASDAQ:TCRX opened at $1.24 on Friday. TScan Therapeutics, Inc. has a 52 week low of $1.02 and a 52 week high of $9.69. The stock’s fifty day moving average is $1.74 and its two-hundred day moving average is $3.24. The stock has a market capitalization of $70.17 million, a price-to-earnings ratio of -1.17 and a beta of 1.09. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. Research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.